Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Vascular effects of nonsteroidal antiinflammatory drugs.

Soubrier M, Rosenbaum D, Tatar Z, Lahaye C, Dubost JJ, Mathieu S.

Joint Bone Spine. 2013 Jul;80(4):358-62. doi: 10.1016/j.jbspin.2012.12.002. Epub 2013 Jun 21. Review.

PMID:
23796731
2.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

3.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
4.

Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA.

Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74.

6.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

7.

The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment.

Chan FK.

Am J Gastroenterol. 2008 Jan;103(1):221-7. Epub 2007 Sep 25.

PMID:
17900323
8.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

9.

Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):223-7.

PMID:
18084859
10.
11.

NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.

[No authors listed]

Prescrire Int. 2016 Jan;25(167):14-6.

PMID:
26942254
13.

Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D.

Br J Clin Pharmacol. 2006 Jun;61(6):730-7. Erratum in: Br J Clin Pharmacol. 2007 May;63(5):635.

15.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

16.

Gastrointestinal safety of low-dose aspirin.

Cryer B.

Am J Manag Care. 2002 Dec;8(22 Suppl):S701-8. Review.

17.

How to advise aspirin use in patients who need NSAIDs.

Sopena F, Lanas A.

Curr Pharm Des. 2007;13(22):2248-60. Review.

PMID:
17691998
18.

Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention.

Vonkeman HE, van de Laar MA.

Semin Arthritis Rheum. 2010 Feb;39(4):294-312. doi: 10.1016/j.semarthrit.2008.08.001. Epub 2008 Sep 27. Review.

PMID:
18823646
19.

Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs.

Hermann M.

Curr Rheumatol Rep. 2009 Feb;11(1):31-5. Review.

PMID:
19171109

Supplemental Content

Support Center